Propofol: Therapeutic indications and side-effects

被引:322
|
作者
Marik, PE [1 ]
机构
[1] Univ Pittsburgh, Dept Critical Care, Med Ctr, Pittsburgh, PA 15261 USA
关键词
propofol; metabisulfite; status epilepticus; status asthmaticus; traumatic brain injury; delirium tremens; sepsis; propofol-infusion syndrome; pancreatitis; allergy;
D O I
10.2174/1381612043382846
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Propofol (2, 6-diisopropylphenol) is a potent intravenous hypnotic agent which is widely used for the induction and maintenance of anesthesia and for sedation in the intensive care unit. Propofol is an oil at room temperature and insoluble in aqueous solution. Present formulations consists of 1% or 2% (w/v) propofol, 10% soyabean oil, 2.25% glycerol. and 1.2% egg phosphatide. Disodium edetate (EDTA) or metabisulfite is added to retard bacterial and fungal growth. Propofol is a global central nervous system depressant. It directly activates GABA(A) receptors. In addition, propofol inhibits the NMDA receptor and modulates calcium influx through slow calcium ion channels. Propofol has a rapid onset of action with a dose-related hypnotic effect. Recovery is rapid even after prolonged use. Propofol decreases cerebral oxygen consumption, reduces intracranial pressure and has potent anti-convulsant properties. It is a potent antioxidant. has anti-inflammatory properties and is a bronchodilator. As a consequence of these properties propofol is being increasingly used in the management of traumatic head injury, status epilepticus, delirium tremens, status asthmaticus and in critically ill septic patients. Propofol has a remarkable safety profile. Dose dependent hypotension is the commonest complication; particularly in volume depleted patients. Hypertriglyceridemia and pancreatitis are uncommon complications. Allergic complications, which may include bronchospasm, have been reported with the formulation containing metabisulfite. In addition, this formulation has been demonstrated to result in the generation of oxygen free radicals. High dose propofol infusions have been associated with the "propofol syndrome"; this is a potentially fatal complication characterized by severe metabolic acidosis and circulatory collapse. This is a rare complication first reported in pediatric patients and believed to be due to decreased transmembrane electrical potential and alteration of electron transport across the inner mitochondrial membrane.
引用
收藏
页码:3639 / 3649
页数:11
相关论文
共 50 条
  • [1] Exploring the associations between drug side-effects and therapeutic indications
    Wang, Fei
    Zhang, Ping
    Cao, Nan
    Hu, Jianying
    Sorrentino, Robert
    [J]. JOURNAL OF BIOMEDICAL INFORMATICS, 2014, 51 : 15 - 23
  • [2] METHOTREXATE - INDICATIONS AND SIDE-EFFECTS
    WOLTER, M
    [J]. HAUTARZT, 1991, 42 (10): : 654 - 654
  • [3] ERYTHROPOIETIN, A THERAPEUTIC AGENT .2. INDICATIONS, SIDE-EFFECTS, AND RISKS
    STASIECKI, P
    POLLOK, M
    BALDAMUS, CA
    [J]. MEDIZINISCHE KLINIK, 1989, 84 (04) : 216 - 218
  • [4] SIDE-EFFECTS AND CONTRA-INDICATIONS
    不详
    [J]. SOUTH AFRICAN MEDICAL JOURNAL, 1972, 46 (25): : 825 - &
  • [5] BASIS FOR THERAPEUTIC USE OF BETA-BLOCKERS - INDICATIONS, CONTRAINDICATIONS AND SIDE-EFFECTS
    HUGUES, FC
    MOUGEOT, G
    [J]. GAZETTE MEDICALE DE FRANCE, 1977, 84 (37): : 4091 - &
  • [6] HYPOSENSIBILIZATION - INDICATIONS, DISPENSING, SIDE-EFFECTS AND THEIR PROPHYLAXIS
    FUCHS, E
    [J]. MEDIZINISCHE WELT, 1986, 37 (42): : 1308 - 1311
  • [7] Steroids in neurooncology: actions, indications, side-effects
    Roth, Patrick
    Wick, Wolfgang
    Weller, Michael
    [J]. CURRENT OPINION IN NEUROLOGY, 2010, 23 (06) : 597 - 602
  • [8] Electroconvulsivotherapy in the elderly, indications, risks and side-effects
    Pereira, S.
    Guimaraes, S.
    Marques, A.
    Borges, S.
    [J]. EUROPEAN PSYCHIATRY, 2008, 23 : S286 - S287
  • [9] SIDE-EFFECTS AND CONTRA-INDICATIONS OF ANTICOAGULANTS
    KOLLER, F
    [J]. THROMBOSIS ET DIATHESIS HAEMORRHAGICA, 1958, 2 (5-6): : 604 - 632
  • [10] PROPHYLAXIS AND TREATMENT OF THERAPEUTIC SIDE-EFFECTS
    GLASER, A
    [J]. DEUTSCHE GESUNDHEITSWESEN-ZEITSCHRIFT FUR KLINISCHE MEDIZIN, 1982, 37 (32): : 1397 - 1401